Discover 3,059 paid clinical trials in Cambridge, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Active & Responsive
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation,
Location: Boston MA, Chicago IL, Minneapolis MN, Los Angeles CA
Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
for
Early Rectal Cancer, Stage I Rectal Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT07735624
Phase 2, Recruiting
Active & Responsive
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, New York NY,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07111520
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
for
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm,
Location: Boston MA, New York NY, Toronto, Hamilton, Detroit MI,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07114601
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer,
Location: Boston MA, Worcester MA, Providence RI, Hartford CT,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT06901531
Phase 3, Recruiting
Active & Responsive
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
for
Breast Cancer
Location: Boston MA, Summit NJ
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT05950945
Phase 3, Recruiting
Active & Responsive
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
for
Bone Pain, Metastatic Malignant Neoplasm in the Bone,
Location: Boston MA, New York NY, Philadelphia PA, Atlanta GA,
Sponsor: University of Southern California
Sex: All
Age: 18+
Code: NCT03858205
Recruiting
Active & Responsive
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Location: Boston MA, Ann Arbor MI, Seattle WA, Stanford CA
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT05922761
Phase 2, Recruiting
Active & Responsive
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
for
Pleuropulmonary Blastoma
Location: Boston MA, Albany NY, Valhalla NY, New Hyde Park NY,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT06647953
Phase 3, Recruiting
Active & Responsive
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
for
Pancreatic Adenocarcinoma Metastatic
Location: Boston MA, Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine
Sex: All
Age: 18+
Code: NCT06747845
Phase 2, Recruiting
Active & Responsive
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
for
CLL/SLL
Location: Boston MA, Canton OH, Cleveland OH, Charlotte NC,
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: Institut de Recherches Internationales Servier
Sex: All
Age: 18+
Code: NCT05786924
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Boston MA, Stony Brook NY, Stamford CT, Nyack NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase 3, Recruiting
Active & Responsive
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders